(Q38749802)

6 September 2017

title

Irradiation and immunotherapy: From concept to the clinic (English)

1 reference

6 September 2017

1 reference

April K S Salama

1

1 reference

6 September 2017

Michael A Postow

series ordinal

2

1 reference

6 September 2017

Joseph K Salama

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

23 February 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

122

1 reference

6 September 2017

issue

11

1 reference

6 September 2017

page(s)

1659-1671

1 reference

Stereotactic body radiotherapy: a critical review for nonradiation oncologists

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Combining radiotherapy and cancer immunotherapy: a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Cytotoxic T-lymphocyte-associated antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radiation-induced cell death mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

The role of tumor stroma in the interaction between tumor and immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Systemic effects of local radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Bystander elimination of antigen loss variants in established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma. Preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Immune modulation and stereotactic radiation: improving local and abscopal responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Ipilimumab and radiation therapy for melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Response assessment criteria for brain metastases: proposal from the RANO group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

The abscopal effect associated with a systemic anti-melanoma immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Awakening the immune system with radiation: Optimal dose and fractionation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Engaging the vascular component of the tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

Advances in radiotherapy and implications for the next century: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

Combination immunotherapy approaches

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

Toxicity of combined treatment of adjuvant irradiation and interferon α2b in high-risk melanoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

Natural alpha-interferon in combination with hyperfractionated radiotherapy in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

Whole body irradiation; radiobiology or medicine?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

An interesting case of possible abscopal effect in malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29889

7 January 2021

Identifiers

DOI

10.1002/CNCR.29889

1 reference

6 September 2017

1 reference